Showing results (71-80 of 1,063) with videos related to
Sort By:
Pageof 107
The Journal of Antimicrobial Chemotherapy|May 1, 1996
Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety GroupP Jaillon, J Morganroth, I Brumpt, et al.Cardiology Clinics|May 1, 1984
Ventricular arrhythmias. Clinical recognition and managementP F Nestico, N L DePace, J MorganrothAnnals of Internal Medicine|February 1, 1975
Type III hyperlipoproteinemia: an analysis of two contemporary definitionsD S Fredrickson, J Morganroth, R I LevyAnnals of Internal Medicine|February 1, 1975
The biochemical, clinical, and genetic features of type III hyperlipoproteinemiaJ Morganroth, R I Levy, D S FredricksonClinical Pharmacology and Therapeutics|December 17, 2009
Evaluation and management of cardiac safety using the electrocardiogram in oncology clinical trials: focus on cardiac repolarization (QTc interval)J Morganroth, R R Shah, J W ScottAnnals of Internal Medicine|September 1, 1976
Cholestyramine: an effective, twice-daily dosage regimenC B Blum, R J Havlik, J MorganrothCirculation|October 1, 1989
Mechanisms and risk factors for proarrhythmia with type Ia compared with Ic antiarrhythmic drug therapyJ H Levine, J Morganroth, A H KadishClinical Therapeutics|January 1, 1986
Oral antiarrhythmic agents for ventricular arrhythmiasM D Meissner, P F Nestico, J MorganrothAnnals of Internal Medicine|September 1, 1985
Tocainide: a new oral antiarrhythmic agentS P Kutalek, J Morganroth, L N HorowitzThe American Journal of Cardiology|February 1, 1980
A new approach to visualize the left main coronary artery using apical cross-sectional echocardiographyS Ogawa, C C Chen, F E Hubbard, et al.Pageof 107